BioTelemetry (BEAT) Tops Q1 EPS by 16c

BioTelemetry (NASDAQ: BEAT) reported Q1 EPS of $0.39, $0.16 better than the analyst estimate of $0.23. Revenue for the quarter came in at $94.5 million versus the consensus estimate of $91.58 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c